Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by JLGeminion Feb 26, 2011 12:23pm
304 Views
Post# 18198993

Reply to Cardu - Closing Act

Reply to Cardu - Closing Act

The last posts by OrdinaryAverageGuy1 and Cardu make a touching closing act to our Shakespearean comedy. 

 

Cardu makes a very personal point that many, if not all, retail investors have been touched by cancer.  For retail investors, investing in Oncolytics and Reolysin has a personal dimension to it.  We were prepared to pay $3 to $6 a share back in 2003 like OrdinaryAverageGuy1 when most institutional investors would not put good money into a unproven idea.  There were practical investment considerations to consider: too much risk, too much time to market.  Cardu makes a personal confession that he is holding Oncolytics until the end and encourages OrdinaryAverageGuy1 to think through his decision to sell.

 

We can only imagine the crescendo the orchestra reaches as OrdinaryAverageGuy1 posts his “Amen” closing lines.  He has seen the light.  He will hold his shares to end too!  The world is saved?

 

OAG1 is the true hero of the comedy for pointing that I’m pumper.  I am accused of not being investor since I trade in shares.  Don’t you love comedy?  JLGemini is the villain, particularly to the cadre involved in the buy side manipulation.  God save the world from pumpers.  There should be a law against pumping.  Invest to see the stock price go down like OAG1 did when ONC fell below $1.50 in 2008.

 

Should OAG1 change his moniker to RipVanWinkle?  Has he been asleep since 2003?  I regularly confess to being a pumper and supporter of Oncolytics.  I classify Brad whiners as “dumpers” and post to counter their deceitful posts encouraging retail investors to sell.  It is not a difficult task since Oncolytics represents a rare investment opportunity and is blatantly being manipulated.  OAG1 is not a fool.  His holdings in ONC have increased since 2003.

 

Let the curtain fall on this farce with Sir Walter Scott’s quote:

            “Oh, what a tangled web we weave,

            When first we practice to deceive!”


LOL
JLGemini

PS Stayed tuned for the 5th post in the series From Ugly Duckling to Market Darling
Bullboard Posts